Alvotech and Dr. Reddy’s Enter into collaboration to co-develop biosimilar candidate to Keytruda® (pembrolizumab).

A phase 2 trial shows promising results for pembrolizumab combined with cisplatin and radiation in treating unresectable ...

Alvotech (NASDAQ:ALVO) and Dr. Reddy’s Laboratories (NYSE:RDY) have entered into a collaboration and license agreement to ...

CHICAGO -- Combining pembrolizumab (Keytruda) with sacituzumab govitecan (SG, Trodelvy) instead of chemotherapy as first-line ...

"These long-term results continue to support [pembrolizumab's] use as a standard of care for patients at increased risk of ...

Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide (Alvotech), and Dr. Reddy's Laboratories announced that ...

Pembrolizumab with sacituzumab govitecan instead of chemotherapy led to improved progression-free survival in PD-L1-postive ...

First-line treatment with sacituzumab govitecan plus pembrolizumab showed significant improvement in PFS vs. chemotherapy ...

Linda Duska, MD, FASCO, MPH, discusses the importance of the KEYNOTE-A18 study reinforcing the new standard of care of pembrolizumab plus concurrent chemoradiotherapy in locally advanced cervical ...

Sacituzumab govitecan plus pembrolizumab improves outcomes vs chemotherapy plus pembrolizumab in patients with previously untreated, PD-L1+ TNBC.

In patients with an aggressive form of breast cancer, treatment with the antibody-drug conjugate sacituzumab govitecan plus ...

As of this writing, the role of PD-L1 inhibitors in prostate cancer remains limited to a subset of patients with metastatic microsatellite instability-high, mismatch repair-deficient, or tumor ...